EUCTR2018-001693-25-DE进行中（未招募）1 期
A single-arm phase II multicenter study of IDH2 (AG 221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Myelodysplastic syndrome according to WHO classification including non-proliferative AML up to 29% of BM blast
- •Age = 18 years
- •Belonging to one of the following categories
- •1. Higher risk MDS (IPSS int-2, high) without response to azacitidine (CR,PR, stable disease with HI) after at least 6 cycles , or relapsing after a response but without overt progression (defined by at least doubling of marrow blasts, compared to pre azacitidine bone marrow, or AML progression beyond 30% blasts)
- •2. Untreated higher risk MDS (IPSS int-2, high) without life threatening cytopenia including ANC <500/mm3 or any recent severe infections and/or platelets below 30,000/mm3 and any bleeding symptom
- •3. Lower risk MDS with resistance or loss of response to a previous treatment with epoetin alpha/ beta (>=60000 U/w) or Darbopoetin (>=250 ug/w) given for at least 12 weeks and RBC transfusion requirement at least 2 U/8 weeks in the previous 16 weeks.
- •Presence of IDH2 mutation in either blood or marrow prior to start of therapy
- •Normal renal function, defined by creatinine less than 1.5 times the upper limit of normal, creatinine clearance (Modification of diet in renal disease) (MDRD) = 50 mL/min.
- •Normal liver function, defined by total bilirubin < 2.0 mg/dl (exception permitted in patients with Gilbert’s Syndrome) and transaminases less than 1.5 times the upper limit of normal.
- •Adequate cardiac ejection fraction (>40%)
- •Patient is not known to be refractory to platelet transfusions.
- •Written informed consent.
- •Patient must understand and voluntarily sign consent form.
- •Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements.
- •ECOG performance status 0-2 at the time of screening.
- •Female subjects of child-bearing potential must agree to undergo medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within 7 days prior to first study drug administration), and on the day of the first study drug administration and confirmed negative prior to dosing and Day 1 before dosing all subsequent cycles.
- •Female subjects of child-bearing potential must agree to undergo medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within 7 days prior to first study drug administration), and on the day of the first study drug administration and confirmed negative prior to dosing and Day 1 before dosing all subsequent cycles.
- •Female subjects with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy. Subjects with reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated at all) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Females of reproductive potential as well as fertile men and their partners who are female of reproductive potential must agree to abstain from sexual intercourse or to use two highly effective forms of contraception from the time of giving informed consent, during the study and for 120 365 days (females and males) following the last dose of AG-221. A highly effective form of contraception is defined as: hormonal oral contraceptives, injectables, patches, intrauterine devices. com
排除标准
- •Severe infection or any other uncontrolled severe condition.
- •Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months.
- •Less than 14 days since prior treatment with growth factors (EPO, G-CSF).
- •Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before the study entry with the exception of hydroxyurea.
- •The patient must have recovered from all acute toxicity from any previous therapy.
- •Subject has a heart-rate corrected QT interval using Fridericia’s method (QTcF) = 470 msec or any other factor that increases the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome). Subjects with prolonged QTcF interval in the setting of bundle branch block may participate in the study.
- •Active cancer or cancer during the year prior to trial entry other than basal cell carcinoma, or carcinoma in situ of the cervix or breast.
- •Patient already enrolled in another therapeutic trial of an investigational drug.
- •Known HIV infection or active hepatitis B or C (test prior to inclusion required).
- •Women who are or could become pregnant or who are currently breastfeeding.
- •Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form.
- •Patient eligible for allogeneic stem cell transplantation.
- •Known allergies to AG-221 or any of its excipients.
- •No affiliation to a health insurance system.
研究者
相似试验
进行中（未招募）
1 期
study of the efficacy of treatment with AG-120 in patients with myelodysplastic syndrome and mutation IDH1Myelodysplastic syndrome, mutation IDH 1, inhibitor IDH-1MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2017-003681-27-FRGroupe Francophone des Myelodysplasies68
进行中（未招募）
1 期
Study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndromeIDH1 mutated mylodysplastic syndromeMedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2017-003681-27-ITGroupe Francophone des Myelodysplasies68
终止
2 期
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NETSmall-cell Lung CancerNeuroendocrine CarcinomaNCT05420636Fox Chase Cancer Center20
进行中（未招募）
2 期
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic SyndromeMyelodysplastic SyndromesLeukemia Acute MyeloidNCT03744390Groupe Francophone des Myelodysplasies68
进行中（未招募）
1 期
A Study of the Effect of Tazemetostat (study drug) in Patients with INI1-Negative Tumors or Relapsed/Refractory Synovial SarcomaCohort 1: Rhabdoid tumors (INI1 or SMARCA4 negative)Cohort 2: Relapsed or refractory synovial sarcoma with SS18-SSX rearrangementCohort 3: Other INI1-deficient/aberrant tumors, including:•Epithelioid sarcoma (ES)•Epithelioid malignant peripheral nerve sheath tumor (EMPNST)•Extraskeletal myxoid chondrosarcoma (EMC)•Myoepithelial carcinoma•Renal medullary carcinoma (RMC)•Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approvalMedDRA version: 18.1Level: LLTClassification code 10007284Term: CarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10064886Term: Renal medullary carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10073134Term: Extraskeletal myxoid chondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10026667Term: Malignant peripheral nerve sheath tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10073335Term: Rhabdoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: HLTClassification code 10015100Term: Epithelioid sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002469-41-FREpizyme, Inc.90